Citius Pharmaceuticals Inc CTXR 深 滬
等待開盤 10-09 09:30:00 美东时间
0.4887
-0.012
-2.47%
華盛通- 最 高0.5207
- 今 開0.49
- 成交量 13.24万股
- 最 低 0.48
- 昨 收 0.5011
- 總市值 1.34万
- 52周最高 2.19
- 市盈率 靜 --
- 換手率 0.48%
- 52周最低 0.4687
- 委 比 95.31%
- 總股本 2.75万
- 歷史最高 137.25
- 量 比 0.70
- 振 幅 8.12%
- 歷史最低 0.4687
- 每 手 1
- 風險率 0.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Citius Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 sales results.
Citius Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 sales results.
08-17 22:24
Citius Pharma Q3 EPS $(0.34) Beats $(0.36) Estimate, Sales $1.494M Miss $5.467M Estimate
Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.36) by 5.56 percent. This is a 57.5 percent increase over losses of $(0.80) per share from the same period last year. The company reported quarterly sales of $1.494 million whi...
08-15 05:07
Citius Oncology Reports 78% QoQ Growth In New Institutional Accounts Ordering LYMPHIR; Near‑Universal Payer Coverage Expands Market Access With Initial CTCL Market Exceeding $400M
New institutional accounts ordering LYMPHIR increased 78% quarter over quarter LYMPHIR's near-universal payer coverage expands market access Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds $400 million CRANFORD, N.J., Aug. 5, 2026 /PRNewswire/ -- Citius Oncology, Inc. (...
08-05 21:22
Citius Oncology Expands LYMPHIR Launch Team Nationwide Ahead Of Full U.S. Deployment In August
Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. by August CRANFORD, N.J., July 21, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Ph...
07-21 21:19
Citius Oncology在ASCO公布LYMPHIR联合帕博利珠单抗治疗妇科肿瘤I期数据
Citius Oncology， Inc．近日在2026年美国临床肿瘤学会年会上，以壁报形式公布了LYMPHIR联合帕博利珠单抗治疗复发或难治性妇科恶性肿瘤...
06-01 22:59
Citius Oncology Presents Phase 1 Clinical Data Of LYMPHIR In Combination With Pembrolizumab In Patients With Recurrent Or Refractory Gynecologic Malignancies At American Society Of Clinical Oncology Annual Meeting
Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today highlighted
06-01 19:21
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
HC Wainwright & Co. Assumes Citius Pharmaceuticals at Buy, Announces Price Target of $4
HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy rating and announces Price Target of $4.
05-18 23:06
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Sunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 635.6% to $2.0...
05-18 20:05
Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility
Citius Pharmaceuticals ( ($CTXR) ) just unveiled an update. On May 4, 2026, Cit...
05-09 06:05
